People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharma, Other Technology, Other Health Care, Healthtech, AI / ML
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allay Therapeutics, Inc. | — | Pharma | Series C | $162.6M | $323.5M | 2019 |
| TWELVE, Inc. | — | Other Technology | Series B | $88.8M | $1.1B | 2010 |
| Miramar Labs Inc | — | Other Health Care | Series B | $87.2M | $95.9M | 2010 |
| Reprieve Cardiovascular, Inc. | — | Other Health Care | Series B | $82.4M | $153.0M | 2020 |
| Apreo Health, Inc. | — | Healthtech | Series C | $81.8M | $513.3M | 2025 |
| ForSight VISION5, Inc. | — | Other Health Care | Series A | $76.8M | $238.2M | 2011 |
| Nexis Vision, Inc. | — | Other Health Care | Series A | $30.3M | $15.1M | 2009 |
| Cotera, Inc. | — | AI / ML | Series A | $14.5M | $4.7M | 2012 |
| Half Moon Medical, Inc. | — | Healthtech | Series A | $8.2M | $8.4M | 2017 |
| ForSight VISION4, Inc. | — | Other Health Care | Series A | $6.0M | $121.1M | 2009 |
| Cabochon Aesthetics Inc | — | Other Health Care | Seed | $4.0M | $9.9M | 2010 |
Hanson S. Gifford III at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hanson S. Gifford III on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.